December 20, 2014 5:44 AM ET


Company Overview of Lupin Pharmaceuticals, Inc.

Company Overview

Lupin Pharmaceuticals, Inc. engages in the development and manufacture of branded and generic pharmaceutical products. It offers generic pharmaceutical products for a range of therapeutic areas; and generic Gatifloxacin Ophthalmic Solution, 0.5% for the treatment of bacterial conjunctivitis. The company also engages in identifying, developing, and marketing prescription drugs for children through distributors in the United States; and manufactures oral and injectable cephalosporin APIs. In addition, it offers oral contraceptives for the prevention of pregnancy in women. Lupin Pharmaceuticals, Inc. was founded in 2003 and is based in Baltimore, Maryland. The company has plants in Mandideep, A...

111 South Calvert Street

Harborplace Tower

21st Floor

Baltimore, MD 21202

United States

Founded in 2003





Key Executives for Lupin Pharmaceuticals, Inc.

Chief Executive Officer and Managing Director
Age: 46
Compensation as of Fiscal Year 2014.

Lupin Pharmaceuticals, Inc. Key Developments

Lupin Pharmaceuticals, Inc. Launches Authorized Generic for Celebrex Capsules

Lupin Pharmaceuticals Inc. has launched the authorized generic for G.D. Searle LLC's Celebrex Capsules (Celebrex) 50 mg, 100 mg, 200 mg and 400 mg strengths.

Lupin Pharmaceuticals Launches Generic Ciprofloxacin in US

Lupin Pharmaceuticals has announced the US launch of a generic version of Bayer's Cipro (ciprofloxacin). LiveMint, the launch follows the US Food and Drug Authority (FDA)'s approval of Lupin's ciprofloxacin 5g/100ml and 10g/100ml oral suspension generic in the treatment of certain bacterial infections. Lupin has reportedly suggested that it was the first company to file an abbreviated new drug application for a ciprofloxacin generic and is therefore eligible for 180 days of market exclusivity.

Lupin Pharmaceuticals Inc. Receives Final Approval for its Niacin ExtendedRelease Tablets USP from the United States Food and Drug Administration

Lupin Pharmaceuticals Inc. has launched its Niacin ExtendedRelease Tablets USP, 500 mg, 750 mg, 1,000 mg strengths having received final approval from the United States Food and Drug Administration (FDA) on March 20, 2014. Lupin's Niacin ExtendedRelease Tablets USP, 500 mg, 750 mg, 1,000 mg strengths are the ABrated generic equivalent of AbbVie Inc.'s Niaspan Tablets 500 mg, 750 mg, 1,000 mg and used with diet to reduce elevated TC, LDLC, Apo B and TG levels, and to increase HDLC in patients with primary hyperlipidemia and mixed dyslipidemia.

Similar Private Companies By Industry

Company Name Region
Bristol-Myers-Squibb Laboratoires Co United States
Prothera, Inc. United States
Nutraceutics Corp. United States
Ion Laboratories, Inc. United States
Janssen Products, LP United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Lupin Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at